Sitemap > News > Oncology
- FDA Approves TORISEL, a Targeted First-in-Class mTOR Inhibitor for the Treatment of Advanced Kidney Cancer
- Peregrine Pharmaceuticals Reports Positive Top-Line Results in Bavituximab Combination Therapy Trial in Advanced Cancer Patients
- Serenex Announces Initiation of Phase 1 Trial for Oral HSP90 Inhibitor, SNX-5422
- Allos Therapeutics Initiates Phase I/II Study of PDX and Gemcitabine in Patients With Non-Hodgkin's Lymphoma or Hodgkin's Disease
- Celsion Completes Enrollment In Phase I Liver Cancer Study
- Epeius Biotechnologies Gains Fda Approval For Two New Clinical Trials Using Rexin-G (Tm) For Breast Cancer And Sarcoma
- Telik Reports Results of TELCYTA® ASSIST-3 Trail
- Telik Announces Top-Line Results of TELCYTA® ASSIST-2 Trial
- Telik Reports Results of TELCYTA® ASSIST-1 Trail
- Additional New Data from Satraplatin SPARC Phase 3 Investigational Trial Presented at ASCO Annual Meeting
- Adding Thalidomide to Standard Therapy Improves Survival in Newly Diagnosed Multiple Myeloma Patients Over Age 75
- Æterna Zentaris Presents Detailed Phase 1 Results for Anti-Cancer Compound AEZS-108 at ASCO Meeting
- ARIAD Presents Additional Efficacy Data on AP23573, Novel mTOR Inhibitor, in Phase 2 Advanced Sarcoma Trial
- ARIAD Presents Positive Efficacy Data On AP23573, Novel mTOR Inhibitor, in Phase 2 Metastatic Endometrial Cancer Trial
- Biweekly Xeloda® Dosing Regimen Is Well Tolerated in Advanced Breast Cancer
- Xeloda® Plus Avastin® Combination Delays Disease Progression in Women with Advanced Breast Cancer
- CAELYX(R) Delays Time to Disease Progression as Maintenance Therapy in Patients with Metastatic Breast Cancer
- Clinical Data Suggest Potential Versatility of ALIMTA® (Pemetrexed for Injection)-Based Regimens in Lung Cancer
- Study Supports Activity of GEMZAR® (Gemcitabine HC1 for Injection) in the Treatment of Early-Stage Breast Cancer
- Targeted, Oral Agent Enzastaurin Shows Favorable Results in Late-Stage Lung Cancer
- EntreMed Presents Phase 2 Results for Panzem® Capsules in Multiple Myeloma
- Exelixis Reports Integrated Data From Phase II Clinical Trials of XL999 at ASCO
- Exelixis Reports Comprehensive XL880 Phase I Data At ASCO
- GlaxoSmithKline reports positive new data On Tykerb® (lapatinib) at the 2007 American Society of Clinical Oncology (ASCO) annual meeting
- 8-year long-term data demonstrate prolonged overall survival and length of disease remission with BEXXAR®
- Investigational Drug CEDIRANIB (AZD2171) Shows Promise In Patients With Recurrent Glioblastoma (GBM)
- Kosan Presents Promising Phase 1 Data on Second-Generation Hsp90 Inhibitor, Alvespimycin, Showing Antitumor Activity in Refractory Breast and Ovarian Cancers at ASCO
- Kosan Presents Phase 1 Data Showing Promising Antitumor Activity and Safety Profile of Epothilone KOS-1584 at ASCO
- Kosan Presents Data on Lead Hsp90 Inhibitor, Tanespimycin, Showing Promising Antitumor Activity in Multiple Myeloma at ASCO
- Kosan Presents Preliminary Phase 2 Data Showing Antitumor Activity of Hsp90 Inhibitor Tanespimycin in Metastatic Melanoma at ASCO
- New Data on Market-Leading VELCADE(R) (Bortezomib) for Injection Further Strengthen Role in Previously Treated Multiple Myeloma
- Millennium Introduces New Oncology Molecule with Activity in Broad Range of Cancer Models
- VELCADE(R) (Bortezomib) for Injection Based Therapy Substantially Improves Event-Free Survival and Complete Response Rate in Newly Diagnosed Multiple Myeloma Patients
- Millennium Advances Aurora A Kinase Program
- Nexavar Significantly Extends Overall Survival by 44% in Liver Cancer Patients
- Pharmacyclics Announces Positive Final Results of Phase 2 Trial of Xcytrin(R) Plus Radiosurgery for Brain Metastases With Occult Tumors Detected in 24% of Patients
- Pharmacyclics Announces Promising Results From Phase 2 Clinical Trial of Xcytrin(R) in Recurrent, Metastatic Non-Small Cell Lung Cancer
- Phase III Ixabepilone Study Demonstrated Significant Improvement in Progression-Free Survival in Patients With Advanced Metastatic Breast Cancer
- Poniard Pharmaceuticals Announces Results of Picoplatin Phase 2 Trial That Confirm and Extend Survival Benefit in Small Cell Lung Cancer
- Poniard Pharmaceuticals Announces Promising Data From Interim Safety Analysis of Phase 1 Combination Trials of Picoplatin in Colorectal and Prostate Cancers
- PTC Therapeutics Presents Phase 1 Results of its Novel VEGF Inhibitor, PTC299, at 43rd American Society of Clinical Oncology (ASCO) Annual Meeting
- RESULTS OF VEGF TRAP (AFLIBERCEPT) HIGHLIGHTED AT ASCO 2007 ANNUAL MEETING
- FOLFOX4 (ELOXATIN®-based chemotherapy) AFTER SURGERY IMPROVES OVERALL SURVIVAL IN PATIENTS WITH EARLY (STAGE III) COLON CANCER
- S-1, A NOVEL ORAL FLUOROPYRIMIDINE, WHEN COMBINED WITH CISPLATIN, DEMONSTRATES SIGNIFICANT IMPROVEMENT IN OVERALL SURVIVAL OF ADVANCED GASTRIC CANCER PATIENTS OVER S-1 ALONE
- THE ELOXATIN®-BASED REGIMEN (FOLFOX4) SIGNIFICANTLY IMPROVED PROGRESSION FREE SURVIVAL WHEN GIVEN BEFORE AND AFTER SURGERY IN PATIENTS WITH RESECTABLE LIVER METASTASES FROM COLORECTAL CANCER
- ELOXATIN® (oxaliplatin injection)-BASED CHEMOTHERAPY SETS NEW TREATMENT BENCHMARK IN PATIENTS WITH METASTATIC COLORECTAL CANCER
- UPDATED STUDY RESULTS REINFORCE SURVIVAL BENEFIT OF TAXOTERE® (DOCETAXEL) FOR MEN WITH ADVANCED, HORMONE-RESISTANT PROSTATE CANCER
- Single-Agent SUTENT Prolonged Progression-Free Survival across All Advanced Kidney Cancer Patient Risk Groups, Including Those with Poorest Prognoses, Data Show
- ABRAXANE Demonstrates Longer Progression-Free Survival versus Taxotere in the Treatment of First-Line Metastatic Breast Cancer
- Study Presented at ASCO Shows Encouraging One-Year and Overall Survival Results for Phase I/II Trial of OGX-011 in Non-Small Cell Lung Cancer.
- Tapestry Pharmaceuticals Presents Phase I Data on TPI 287 at the 43rd ASCO Annual Meeting
- Thallion announces publication of ECO-4601 PHASE I/II clinical data at ASCO
- Xanthus Announces Phase 1 Results for P2045 – A Targeted Agent for Non-small Cell Lung Cancer
- Xanthus Presents Phase 2 Data Showing Xanafide is Associated with Complete Remissions in Secondary AML
- ZIO-101 Oral Capsule Clears FDA Review for Phase I Study
- ZIO-101 (Darinaparsin) Early Interim Multiple Myeloma Phase I/II Data Presented at ASCO
- ZIO-101 (Darinaparsin) Phase I Advanced Solid Tumor Data Presented at ASCO
- ZIO-301 (Indibulin) Interim Phase I Data Presented at ASCO
- Genta Announces Results of Phase 1 Study using Genasense Administered by Intermittent Subcutaneous Injection
- Gloucester Pharmaceuticals Reports Positive Interim Phase II Data on Romidepsin for T-Cell Lymphomas at the 2007 American Society of Clinical Oncology Annual Meeting
- INNOVIVE Pharmaceuticals Receives FDA Fast Track Designation for Tamibarotene for the Treatment of Acute Promyelocytic Leukemia
- NOVELOS THERAPEUTICS ANNOUNCES ENROLLMENT OF 1st PATIENT IN PHASE 2 BREAST CANCER TRIAL
- Synta Presents Results for STA-4783 in Metastatic Melanoma Showing Improvement in Overall Survival
- TELIK ANNOUNCES CLINICAL HOLD ON TELCYTA
- Phase III clinical trial with 4-month long-acting formulation of triptorelin: Ipsen decides not to perform further administration
- GSK and Adolor Update Alvimopan (Entereg/Entrareg) Development Program
- Pro-Pharmaceuticals Submits Data to Begin a 505 (b)(2) Filing with the FDA for a New Formulation of Irinotecan to be Co-administered with DAVANAT as a Functional Excipient
- Vion Presents Clinical Data from a Phase II Trial of Cloretazine® (VNP40101M) in Elderly AML Patients with Unfavorable Cytogenetics at EHA Meeting
- Xanthus Completes Special Protocol Assessment with FDA for Phase 3 Registration Trial of Xanafide in Patients with Secondary Acute Myeloid Leukemia
- GERON’S TELOMERASE INHIBITOR CANCER DRUG DEMONSTRATES GOOD PHARMACOKINETICS AND TOLERABILITY IN PHASE I/II TRIAL
- FDA grants priority review for oral formulation of HYCAMTIN (topotecan) to treat relapsed small cell lung cancer
- Chroma Progresses Novel Cancer Therapy CHR-2797 Into Phase II Solid Tumour Study
- Avalon Updates the AVN944 Phase I Hematologic Malignancies Trial
- FDA Converts TELCYTA Full Clinical Hold to Partial Hold
- NOVELOS THERAPEUTICS ANNOUNCES ENCOURAGING RESULTS IN ONGOING PHASE 2 OVARIAN CANCER TRIAL AT DANA-FARBER/PARTNERS CANCER CARE
- NicOx provides an update on NCX 4016
- Vical Licensee AnGes MG Announces Positive Results of Phase 3 Angiogenesis Trial in Japan
- Allos Therapeutics Reports Results for Phase 3 Enrich Study of Efaproxyn in Women With Brain Metastases Originating From Breast Cancer
- Bayer and Onyx Submit New European Marketing Authorization Application to EMEA for Nexavar to Treat Liver Cancer
- OSI Pharmaceuticals Begins Clinical Development Program of OSI-906 in Patients with Advanced Solid Tumors
- FDA Grants Priority Review for Bristol-Myers Squibb
- Merck Provides Update on Status of Supplemental Biologics License Applications (sBLA) for GARDASIL
- Myriad Genetics Collaborates With AstraZeneca on Phase 2 Trials to Determine If Women With BRCA1 & BRCA2 Mutations May Receive Greater Benefit From New Treatment
- GlaxoSmithKline’s Atriance (nelarabine) receives positive opinion in Europe for the treatment of rare, difficult to treat leukaemias and lymphomas
- Pharmion Submits European Marketing Authorization Application for Satraplatin in Combination With Prednisone for the Treatment of Patients With Metastatic Hormone-Refractory Prostate Cancer Who Have Failed Prior Chemotherapy
- YM BioSciences Receives FDA Clearance for an IND for its Fentanyl-Based Pain Product AeroLEF
- Pfizer Initiates Phase III Trial to Study Sunitinib Malate in Patients with Metastatic Colorectal Cancer
- Pharmacyclics Announces Interim Results From Two Ongoing Phase 2 Trials Supporting Potential of Xcytrin Plus Chemotherapy to Treat Recurrent Non-Small Cell Lung Cancer
- ZIO-101 (Darinaparsin) Interim Phase II and Preclinical Data Presented at International Myeloma Workshop
- Cytogen Presents Phase 1 Data Showing Promising Antitumor Activity and Safety Profile of QUADRAMET(R) at International Myeloma Workshop
- VELCADE(R) (Bortezomib) for Injection Addressed Disease-Related Complications Associated with Multiple Myeloma
- VELCADE(R) (Bortezomib) for Injection Based Therapies Produced Complete Remission Rates as High as 54 Percent in Patients With Previously Treated Multiple Myeloma
- Printer Friendly Version VELCADE(R) (Bortezomib) for Injection Based Therapies Achieved Survival Rates as High as 100 Percent in Newly Diagnosed Multiple Myeloma Patients
- Cylene Pharmaceuticals’ Ribosomal RNA Biogenesis Inhibitor, Quarfloxin (CX-3543), Enters Phase II Clinical Trial
- Cytokinetics Reports Additional Clinical Trials Data for Ispinesib
- Cyclacel Pharmaceuticals initiates Phase I study of CYC116 in patients with advanced solid tumors
- Keryx Biopharmaceuticals, Inc. Announces Positive Phase I and Phase II Data on KRX-0401 in Patients with Relapsed/Refractory Multiple Myeloma and Waldenstrom's Macroglobulinemia
- VELCADE(R) (bortezomib) for Injection Based Induction Therapy Delivered High Post-Transplant Complete Remission Rate, a Critical Marker for Increased Overall Survival
- EpiCept Accelerates Development of EPC2407 for Cancer
- GTx Initiates Phase IIb Ostarine Clinical Trial for Cancer Cachexia
- Biomira files investigational new drug application for PX-478, a novel inhibitor of hypoxia-inducible factor-1 alpha
- Maxygen Initiates Phase IIa Clinical Trial of MAXY-G34 in Breast Cancer Patients
- SuperGen Reports Dosing of First Patient in Phase I Trial of Novel Tyrosine Kinase Inhibitor
- MGI PHARMA and HELSINN Announce Aloxi sNDA for PONV Accepted for Review By U.S. FDA
- BIOCRYST RECEIVES SPECIAL PROTOCOL ASSESSMENT FOR PIVOTAL TRIAL OF ORAL FODOSINE IN PATIENTS WITH CUTANEOUS T-CELL LYMPHOMA
- GERON INITIATES CLINICAL TRIAL OF TELOMERASE INHIBITOR DRUG IN COMBINATION WITH PACLITAXEL AND CARBOPLATIN IN PATIENTS WITH NON-SMALL CELL LUNG CANCER
- OXiGENE Begins Pivotal Registration Study for ZYBRESTAT in Anaplastic Thyroid Cancer
- Positive ZIO-201 Interim Phase II Sarcoma Data Presented at European Society for Medical Oncology
- ProMetic reports positive preliminary phase Ib/II data for PBI-1402 in chemotherapy-induced anemia
- ProMetic reports positive preliminary phase Ib/II data for PBI-1402 in chemotherapy-induced anemia
- Progen Pharmaceuticals Outlines Preliminary Phase 3 Clinical Trial Design
- Progen Pharmaceuticals Outlines Preliminary Phase 3 Clinical Trial Design
- Prolarix dose selected for phase 2 liver cancer study
- ARIAD and Merck & Co., Inc. Announce Global Collaboration to Jointly Develop and Commercialize AP23573 - ARIAD's Novel mTOR Inhibitor - for Cancer
- GTx's Phase III Clinical Development of ACAPODENE on Course Following Planned Safety Review
- MethylGene Initiates Phase II Clinical Trial in Chronic Lymphocytic Leukemia
- Rigel Announces Start of Phase 1 Combination Therapy Study of R763/AS703569 in Advanced Malignancies
- FDA Approves First Gene- Based Test To Detect The Spread Of Breast Cancer Into Lymph Nodes
- Cougar Biotechnology Announces Allowance of IND for CB 3304 (Noscapine)
- Genzyme Announces Phase 3 Trial of Mozobil in non-Hodgkin’s Lymphoma Meets Primary Endpoint
- Light Sciences Oncology Initiates Phase III Trial of Its Light Infusion Therapy (Litx) in Patients with Metastatic Colorectal Cancer
- YONDELIS RECEIVES POSITIVE OPINION IN EUROPE FOR THE TREATMENT OF SOFT TISSUE SARCOMA
- EMEA Indicates that Genasense Approval in Melanoma Will Require Confirmatory Clinical Trial
- Src kinase inhibitor KX2-391 Allowed to Proceed to Phase 1 Trials
- EpiCept Announces Phase III Study of EpiCept NP-1 for the Treatment of Chemotherapy Induced Peripheral Neuropathy
- Nventa Announces Publication Of Final Results Of A Phase 2 Study Of HspE7 In Cervical Dysplasia
- IDM Pharma Announces Plans to Amend New Drug Application for Mifamurtide (L-MTP-PE) for the Treatment of Patients with Osteosarcoma
- FDA Oncologic Drugs Advisory Committee Recommends that FDA Wait for Overall Survival Results from Satraplatin Phase 3 Trial
- EntreMed Commences Leukemia Clinical Trial for MKC-1 in Canada
- Medivation Announces Treatment of First Patient in Phase 1-2 Clinical Trial of MDV3100 in Hormone-Refractory Prostate Cancer
- Exelixis Retains Right to Develop and Commercialize XL647
- Threshold Pharmaceuticals Initiates Phase 1 Clinical Trial Evaluating TH-302 in Patients With Solid Tumors
- Javelin Pharmaceuticals Initiates Phase 3 Breakthrough Cancer Pain Trial for Intranasal Ketamine
- OncoGenex and Isis Report Encouraging Interim Phase II Data in Advanced Prostate Cancer, Affirm Phase III Clinical Trial Plans
- Poniard Pharmaceuticals Announces Initiation of Picoplatin Phase 2 Trial in First-line Treatment of Hormone-Refractory Prostate Cancer in Combination with Docetaxel and Prednisone
- Genta and Emisphere Technologies File IND with FDA for Oral Drug to Treat Bone Disease
- Antigenics Provides Update on Filing for Approval of Oncophage in Russia for the Treatment of Intermediate-Risk Kidney Cancer
- Enzon Commences Enrollment of Two Phase 1 Studies of PEG-SN38 for Advanced Solid Tumors and Lymphoma
- Kosan Opens Registration Program for Lead Hsp90 Inhibitor, Tanespimycin, in Multiple Myeloma
- Genzyme Announces Second Pivotal Mozobil Trial Meets Primary Endpoint
- Vidaza Significantly Extends Overall Survival by 74% in Phase 3 Trial in Myelodysplastic Syndromes (MDS)
- Hana Biosciences Initiates Marqibo) Phase 2 Clinical Trial in Relapsed Acute Lymphoblastic Leukemia (All)
- Antisoma starts phase II trial of AS1411 in acute myeloid leukaemia
- Array BioPharma Advances ErbB-2 Inhibitor, ARRY-380, into Phase 1 Cancer Patient Trial
- INNOVIVE Pharmaceuticals Reaches Agreement with FDA on Special Protocol Assessment for Pivotal Phase II Clinical Trial with Tamibarotene in Refractory Acute Promyelocytic Leukemia
- BioCancell reports completion of first part of clinical trial
- Phase I Intravenous Trial Achieves Primary Objectives
- FDA Approves IND for Phase II Studies of TASQ
- Cytokinetics Announces the Initiation of a Phase I Clinical Trial for GSK-923295
- Allos Therapeutics Initiates Study of PDX in Patients with Cutaneous T-Cell Lymphoma
- Millennium Initiates Clinical Trial to EVOLVE the Treatment of Patients with Newly Diagnosed Multiple Myeloma
- EMEA Recommends Orphan Drug Designation for PI-88
- Vion Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine® (VNP40101M) in Elderly AML
- Myriad Genetics Initiates Phase 2 Clinical Trial of Azixa in Lung Cancer
- ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
- Bioenvision Provides Evoltra (clofarabine) Regulatory Update
- Indevus Receives Approvable Letter From FDA for VALSTAR for Bladder Cancer Therapy
- Pro-Pharmaceuticals Announces “Compassionate Use” IND for DANANAT to Treat Biliary Cancer Patient.
- Nexavar Granted FDA Priority Review for Treatment of Liver Cancer
- Access Pharmaceuticals Provides Update on Clinical Development Plan of ProLindac
- Antisoma’s ASA404 1800 mg/m2 lung cancer trial will report positive survival data
- Pharmion and MethylGene Announce U.S. Orphan Drug Designation Granted for MGCD0103 for the Treatment of Hodgkin's Lymphoma
- Hana Biosciences Receives Fast Track Designation for Marqibo for the Treatment of Relapsed Acute Lymphoblastic Leukemia
- THALLION SUCCESSFULLY COMPLETES ECO-4601 CLINICAL PHASE I/II STUDY IN ONCOLOGY
- Phase 3 Oncology Program for Aflibercept (VEGF Trap) Initiated by Regeneron and sanofi-aventis
- GlaxoSmithKline Accelerates Review of Exelixis' XL880
- Ascenta Therapeutics Presents New Clinical Data on AT-101 for the Treatment of Hormone-Refractory Prostate Cancer
- Nexavar Significantly Improved Overall Survival in Phase III Asia-Pacific Liver Cancer Trial
- DIAMYD UPDATES GENE THERAPY PROGRAM AND OUTLINES PLANS FOR PHASE I CLINICAL TRIAL FOR TREATMENT OF CANCER PAIN
- First patient enrolled in Europe in Ovature Phase III ovarian cancer trial
- Advanced Life Sciences Announces ALS-357 Granted FDA Orphan Drug Designation for Metastatic Melanoma
- Biomira initiates Phase 1 trial of PX-478 in patients with advanced metastatic cancers
- CuraGen and TopoTarget Initiate Phase I/II Clinical Trial of Belinostat (PXD101) Combination Therapy for Acute Myeloid Leukemia
- Ambrilia completes patient recruitment for the phase 3 pivotal clinical trial of its prolonged release formulation of Octreotide
- Pharmion\'s Oral Azacitidine Granted Fast Track Status for Myelodysplastic Syndromes
- Prolexys Pharmaceuticals Initiates Phase 1 Study - Novel Agent Administered in First-In-Human Study to Cancer Patients
- Kiadis Pharma Announces Promising Phase II Clinical Trial Results for Reviroc
- MGI PHARMA and HELSINN Announce Aloxi(R) sNDA Approval Allowing for Repeated Dosing for Cancer Patients Receiving Multiple Day Chemotherapy Regimens
- Poniard Pharmaceuticals Receives FDA Fast Track Designation for Picoplatin for Treatment of Small Cell Lung Cancer
- Exelixis Reports Encouraging Interim Data From a Phase 2 Trial of XL647 as First-Line Therapy for Non-Small Cell Lung Cancer
- Advanced Viral Research Corp. to Initiate Phase II Trial in Cancer Patients
- Provectus Pharmaceuticals, Inc. Begins Phase 2 Clinical Trial for Metastatic Melanoma
- Pfizer Oncology Initiates Global Phase III Trial to Evaluate Sunitinib Malate Combined with Erlotinib in Advanced Non-Small Cell Lung Cancer
- Discussions With FDA on Pixantrone EXTEND (PIX301) Trial Provide Path for NDA Submission
- Kosan Receives Completed Special Protocol Assessment for TIME-1 Pivotal Phase 3 Trial of Tanespimycin in Multiple Myeloma
- Idera Pharmaceuticals Presents Interim Data from Phase 1 Study Evaluating IMO-2055 in Combination with Gemcitabine and Carboplatin
- Aranesp Study Showing No Negative Impact on Survival in SCLC
- Boehringer Ingelheim to initiate first Phase III pivotal study for new oncology compound BIBW 2992
- Kosan\'s Second-Generation Hsp90 Inhibitor, Alvespimycin, Shows 42% Clinical Benefit in Phase 1 HER2-Positive Metastatic Breast Cancer Trial
- OSI Pharmaceuticals Summarizes Data Presented on Tarceva(R) (erlotinib) at the 12th World Congress on Lung Cancer Meeting
- Spectrum Pharmaceuticals Initiates Second Registrational Phase 3 Clinical Trial for EOquin(R) in Patients With Non-Invasive Bladder Cancer
- Bioniche Reaches Special Protocol Assessment Agreement with U.S. FDA for Phase III Comparative Bladder Cancer Trial
- ADVENTRX Announces ANX-514 Clinical Development Plan Affirmed by the FDA
- ARIAD Announces Agreement with FDA on Special Protocol Assessment for Phase 3 Clinical Trial of Oral Deforolimus
- EntreMed Presents Data for Phase 2 Study of MKC-1 in Metastatic Breast Cancer
- Metabasis Announces Orphan Drug Designation Granted to MB07133, Its Product Candidate for the Treatment of Primary Liver Cancer
- Neose Announces Initiation of Phase II Renal Trial of NE-180
- Xeloda® XeNA Study Analyses of Xeloda, Docetaxel and Herceptin Combination Therapy for Metastatic Breast Cancer Featured at Major New Breast Cancer Symposium
- ZIOPHARM Treats Patients in U.S. Phase I Trials of Oral Darinaparsin and Indibulin
- Cell Therapeutics, Inc. (CTI) Launches Phase III Study for Pixantrone in Relapsed Indolent Non-Hodgkin\'s Lymphoma (NHL)
- Alfacell Updates Status of ONCONASE(R) Phase III Clinical Program
- Sunesis Pharmaceuticals Commences Clinical Trials of SNS-595 and SNS-314
- FDA Accepts ISO-Vorin(TM) New Drug Application Amendment Submitted by Spectrum Pharmaceuticals
- FDA Approves Lilly\'s Osteoporosis Drug EVISTA® (raloxifene HCl) to Reduce The Risk of Invasive Breast Cancer in Two Populations of Postmenopausal Women
- Genta Initiates First Clinical Trial with New Oral Drug (G4544) to Treat Bone Disease
- Vion Announces Initiation of a Phase I/II Trial of Cloretazine® (VNP40101M) in Combination with Temodar® in Adult Brain Tumors
- Phase III Clinical Trial in Newly Diagnosed Multiple Myeloma Stopped Early Due to Highly Significant Efficacy Advantage of VELCADE(R) (Bortezomib) for Injection Based Therapy Across All Endpoints
- Provectus Pharmaceuticals, Inc. Releases Summary Results of Phase 1 Metastatic Melanoma Study
- European Committee Issues Positive Opinion on Wyeth\'s TORISEL for Advanced Renal Cell Carcinoma
- Callisto Pharmaceuticals Completes Enrollment of Phase II Trial of Atiprimod in Neuroendocrine Cancer
- Lilly Files for European Approval of ALIMTA® (pemetrexed for injection) for First-Line Treatment of Non-Small Cell Lung Cancer
- FDA Approves Expanded Labeling for Campath to Include First-line Treatment for Leading Form of Adult Leukemia
- Tasigna® recommended for European approval to treat rare form of leukemia no longer responding to Glivec®
- ARIAD Initiates Phase 3 \'Succeed\' Trial of Oral Deforolimus in Patients with Metastatic Sarcomas
- Cell Therapeutics, Inc. (CTI) Receives SPA Approval from FDA and Launches Gender-Specific Phase III Trial for Advanced Non-Small Cell Lung Cancer
- Printer Friendly Version Interim Response and Safety Analyses Support Continuation of Allos Therapeutics\' Pivotal Phase 2 PROPEL Trial of PDX in Patients with Peripheral T-Cell Lymphoma
- Phase 3 Pivotal Trial of TOCOSOL® Paclitaxel Does Not Meet Primary Endpoint
- US FDA Fast Tracks PI-88 for the Treatment of Post Resection Liver Cancer
- Progen Announces PI-88 Phase 2 Lung Cancer Results
- Nexavar® Receives Positive Opinion from European Committee for Medicinal Products for Human Use for Treatment of Liver Cancer
- Halozyme Therapeutics Completes Enrollment in Chemophase Phase I/IIa Clinical Trial for Superficial Bladder Cancer
- Phase 2 Study Suggests That Extended Dosing of Aranesp(R) is as Efficacious as Weekly Dosing
- Herceptin eradicates tumours and may reduce the need for mastectomies in women with inflammatory HER2-positive breast cancer - one of the most aggressive and fastest growing forms of the disease
- Glufosfamide Results From Phase 3 Clinical Trial Presented at European Cancer Conference (ECCO)
- Positive Glufosfamide Results From a Phase 2 Clinical Trial Presented at European Cancer Conference (ECCO)
- Phase 3 Pivotal Trial of TOCOSOL® Paclitaxel Does Not Meet Primary Endpoint
- ARIAD Initiates Phase 3 \'Succeed\' Trial of Oral Deforolimus in Patients with Metastatic Sarcomas
- FDA Warns of Potential Serious Side Effects with Breakthrough Cancer Pain Drug
- New Preliminary Phase II Data Show Anti-Tumor Activity of Single-Agent Sunitinib Malate in Advanced Gastric Cancer
- InSightec Resumes Clinical Trials for Non-Invasive Treatment of Brain Tumors
- Positive ZIO-201 Interim Phase II Sarcoma Data Presented at European College of Clinical Oncology Annual (ECCO) Meeting
- Amgen Receives Proposal for Amending EU Prescribing Information for Aranesp(R)
- Positive Xeloda® Five-Year Overall Survival Study Data
- ADVENTRX Pharmaceuticals Announces Results From Phase 2b Clinical Trial of ANX-510 (CoFactor(R))
- Taxotere® (docetaxel) granted FDA approval to treat Locally Advanced Head and Neck Cancer prior to chemoradiotherapy and surgery
- Ardea Biosciences\' Lead MEK Inhibitor, RDEA119, to Enter Human Clinical Trials in Advanced Cancer Patients
- ChemGenex Announces Positive Preliminary Data from Phase 2/3 Clinical Trial of Ceflatonin® at International Conference
- Chemokine Therapeutics Completes Patient Recruitment Of CTCE-9908 Phase I/II Clinical Trial CTCE-9908 Phase I/II Clinical Trial
- Tapestry Initiates Phase 2 Trial of TPI 287 for the Treatment of Advanced Pancreatic Cancer
- EpiCept Announces Successful Completion of Enrollment for Phase I Trial of EPC2407
- Interim analysis of phase IIa AK trial
- First Patient Enrolled in Phase II Cancer Trial
- Xanthus Initiates Pivotal Phase 3 Trial of Xanafide in Secondary Acute Myeloid Leukemia
- Proteolix Initiates Multicenter Open-label Study of the Safety and Activity of Carfilzomib in Subjects with Relapsed Solid Tumors
- ADVENTRX Announces Completion of Patient Enrollment in ANX-530 Marketing-Enabling Clinical Study
- CuraGen Announces Top-Line Phase II Results on Velafermin
- MethylGene and Pharmion Initiate Phase I Combination Trial with MGCD0103 and Taxotere in Patients with Solid Tumors
- VioQuest Pharmaceuticals Completes Enrollment of Phase I Trial of Lenocta™
- BIOCRYST INITIATES ENROLLMENT IN PIVOTAL TRIAL OF FORODESINE HCL IN PATIENTS WITH CUTANEOUS T-CELL LYMPHOMA (CTCL)
- Threshold Pharmaceuticals to Stop Enrollment in Clinical Trial
- Abraxis Bioscience Reaches Agreement with the FDA Following Special Protocol Assessment for Phase III Trial of ABRAXANE in Non-Small Cell Lung Cancer
- Antisoma encouraged by ASA404 prostate cancer data
- FDA Removes Partial Hold on TELCYTA Clinical Development
- FDA Expands VELCADE(R) (Bortezomib) for Injection Label for Patients with Multiple Myeloma
- GSK receives approval for Hycamtin® (topotecan) capsules for the treatment of relapsed small cell lung cancer
- FDA Approves IXEMPRA™ (ixabepilone), a Semi-Synthetic Analog of Epothilone B, for the Treatment of Advanced Breast Cancer
- Curis, Inc. Announces Initiation of Expansion Cohort in Collaborator Genentech\'s Phase I Clinical Trial of a Systemically Administered Hedgehog Antagonist
- Aperio Receives FDA Approval for HER2 Image Analysis Application
- Authorization for AGENDA Phase 3 Trial of Genasense® in Advanced Melanoma Granted by French Regulatory Agency
- Molecular Insight Pharmaceuticals, Inc. Announces Positive Results of Azedra(TM) Phase 1 Dosimetry Trial for Neuroendocrine Tumors
- Osiris Therapeutics Receives FDA Clearance to Initiate Phase III Pivotal Trial for Prochymal™ as a First Line Treatment for Acute Graft vs. Host Disease
- U.S. Oncology Initiates Complete Phase Ib Trial of Brostallicin Combination Therapy in Advanced Solid Tumors
- Poniard Pharmaceuticals Announces European Commission Grants Orphan Medicinal Product Designation to Picoplatin for Treatment of Small Cell Lung Cancer
- Pharmion Initiates Pivotal Phase 3 Study of Amrubicin in Small Cell Lung Cancer
- Abraxis BioScience Receives a Positive Opinion in Europe from the CHMP for the Approval of ABRAXANE for the Treatment of Metastatic Breast Cancer
- Tarceva approved for lung cancer in Japan
- Taxotere® receives positive opinion from the Committee for Medicinal Products for Human Use (CHMP) recommending approval in the European Union for induction treatment for locally advanced Head and Neck cancer
- ASCO and ASH Release Updated Guideline on the Use of Chemotherapy-Related Anemia Treatments in Cancer Patients
- CF102 Drug is Effective in Promoting Liver Tissue Regeneration; Clinical Trials with CF102 in the Treatment of Liver Cancer are Due to Commence in Early 2008
- Sunesis Pharmaceuticals Reports Preliminary SNS-595 Activity in Ovarian Cancer Clinical Trial at AACR-NCI-EORTC International Conference
- Cephalon Announces Positive Results from Its Pivotal Study of TREANDA in Patients with Non-Hodgkin\'s Lymphoma
- Genasense® Can be Administered by Brief High-Dose IV Infusion
- Jennerex Presents Clinical Data From JX-594 Demonstrating Tumor Efficacy Against Advanced Liver Cancers
- Kosan Presents Phase 1 Data Showing Antitumor Activity and Safety Profile of Epothilone KOS-1584 at AACR/NCI/EORTC Meeting
- NCCN Updates Central Nervous System Cancers Guidelines
- NCCN Updates Multiple Myeloma Guidelines
- NCCN Updates Non-Small Cell Lung Cancer Guidelines
- Updated Phase 1 Data for Exelixis\' XL184 Demonstrate Pharmacodynamic and Clinical Anti-Tumor Activity
- ZymoGenetics Reports Positive Phase 1 Results for IL-21 With Nexavar
- ArQule Announces Clinical and Pre-Clinical Data on Anti-Metastatic Potential of ARQ 197, a Selective c-Met Inhibitor
- Array BioPharma Reports Positive New Data on ErbB-2 / EGFR Inhibitor, ARRY-543
- OXiGENE Reports OXi4503 Phase I Interim Data; Mechanism-of-Action Data Published in Peer-Review Journal
- Pharmion and MethylGene Report Preliminary MGCD0103 Clinical Data at the 2007 AACR-NCI-EORTC International Conference
- RTA 402 Phase 1 Results Presented at AACR-NCI-EORTC Conference; Exceptional Tolerability with Significant Anti-Cancer Activity
- Infinity and MedImmune Present Preliminary Phase 1 Data Demonstrating Biological Activity of IPI-504, a Novel HSP90 Inhibitor, in Advanced Non-Small Cell Lung Cancer
- EntreMed Reports Phase 1 PK and Preclinical Efficacy Results for ENMD-1198
- Elan Announces the Johnson & Johnson Pharmaceutical Research & Development Submission of a New Drug Application to the FDA for Paliperidone Palmitate Using Elan\'s Proprietary NanoCrystal® Technology
- DIAMICS RECEIVES EUROPEAN CE MARK APPROVAL FOR ITS PAP-MAP™ SYSTEM FOR CERVICAL CANCER SCREENING
- Tasigna® receives US approval providing new hope to chronic myeloid leukemia patients with resistance or intolerance to existing therapies
- Long-Term Data from a Landmark Phase III Trial Show Survival Benefit at Three- and Four-Years in Patients with Glioblastoma multiforme
- TransMolecular Reports Positive Phase 1 Trial of 131Iodine Radiolabeled TM-601 in Glioma
- Nexavar® Becomes First and Only Approved Treatment of Hepatocellular Carcinoma in Europe
- GPC Biotech and Pharmion Announce Results of Overall Survival Analysis from the Satraplatin Pivotal Phase 3 Trial
- Enzon Initiates Second Phase 1 Study of Its HIF-1 Alpha Antagonist
- ArQule Announces Initiation of Two Phase 2 Trials with c-Met Inhibitor, ARQ 197
- Alfacell\'s ONCONASE(R) Shows Promise as Radiation Sensitizer for Lung Cancer Treatment
- Adherex and The International Childhood Liver Tumour Strategy Group (SIOPEL) Announce The Launch Of A Phase III Trial Of STS
- Encouraging Preliminary Data from TNFerade™ Phase II Rectal Cancer Study Presented at ASTRO Meeting
- ADVENTRX Provides Update on Cofactor(R) Program
- IDM Pharma Announces Data Presentation From Mifamurtide (L-MTP-PE) Compassionate Use Program
- IDM Pharma Announces Updated Phase 3 Mifamurtide (L-MTP-PE) Data Confirms Statistically Superior Overall Survival in Osteosarcoma Patients
- Medivation\'s MDV3100 Demonstrates Substantial PSA Reductions in First Patient Groups Treated in Phase 1-2 Hormone Refractory Prostate Cancer Trial
- Poniard Pharmaceuticals Initiates Randomized Phase 2 Trial of Picoplatin for First-Line Treatment of Metastatic Colorectal Cancer
- Progen Presents Additional Analysis of Data from PI-88 Phase 2 Liver Cancer Study at AASLD
- Protox Announces Positive Final Data From Prostate Cancer Study
- Keryx Biopharmaceuticals, Inc. Announces Positive Preliminary Phase 2 Data on KRX-0401 in Patients with Chemo-Insensitive Rare Sarcoma
- Novacea Halts ASCENT-2 Trial in Advanced Prostate Cancer
- ZIOPHARM Presents Positive Phase II Data for ZIO-201 in Soft Tissue and Bone Sarcomas at Connective Tissue Oncology Society (CTOS) Annual Meeting
- Results from Phase 1 Study of AVEO’s Novel Triple VEGF Receptor Inhibitor AV-951 Show 100% of Renal Cell Cancer Patients Achieved Partial Response or Stable Disease
- Poniard Pharmaceuticals Announces Positive Preliminary Bioavailability Data From Ongoing Phase 1 Trial of Oral Picoplatin in Patients With Solid Tumors
- Results from Phase 1 Study of AVEO’s Novel Triple VEGF Receptor Inhibitor AV-951 Show 100% of Renal Cell Cancer Patients Achieved Partial Response or Stable Disease
- Synta Pharmaceuticals Initiates Phase 1 Clinical Trial of STA-9090, a Novel Hsp90 Inhibitor
- FDA Strengthens Boxed Warnings, Approves Other Safety Labeling Changes for Erythropoiesis-Stimulating Agents
- FDA Approves New SPRYCEL® (Dasatinib) Product Labeling for Patients with Chronic-Phase CML
- Seattle Genetics Initiates Phase IIb Clinical Trial of SGN-33 in Combination with Chemotherapy for Acute Myeloid Leukemia
- AngioDynamics Highlights Study Showing Significant 5-Year Survival After Ablation of Colorectal Liver Metastases
- BioGeneriX and Neose Technologies Announce Positive Data from Two Phase I Studies of GlycoPEG-GCSF
- Synta Reaches Agreement on Special Protocol Assessment and Initiates SYMMETRY Trial - a Pivotal Phase 3 Clinical Trial of Elesclomol in Metastatic Melanoma
- Allos Therapeutics Initiates Study of RH1 in Patients with Advanced Solid Tumors or non-Hodgkin\'s Lymphoma
- Introgen and Gendux Submit First Marketing Authorization Application for ADVEXIN
- Infinity and MedImmune Initiate Phase 2 Clinical Trial of IPI-504, a Novel Hsp90 Inhibitor, in Patients with Advanced Hormone-Refractory Prostate Cancer
- Cytopia reports Final Data from Phase I Cancer Trial
- Æterna Zentaris Announces Completion of Patient Enrollment for Multi-Center Phase 2 Trial with Perifosine in Combination with Radiotherapy for Non-Small Cell Lung Cancer
- Panacea Pharmaceuticals Announces the Availability of BC Detectsm, a Serum-Based Diagnostic Test for Breast Cancer
- Thallion Announces Positive Safety and Efficacy Data from ECO-4601 Phase I/II Trial
- INNOVIVE Pharmaceuticals Initiates Pivotal Phase II Clinical Trial with Tamibarotene
- EXACT Sciences Announces Results of Multi-Center Study of Version 2 Stool DNA Technology for Colorectal Cancer Screening
- BiPar Genomic Biomarker Data Demonstrate Overexpression of PARP1 Gene in Multiple Cancer Types
- Genta Completes Initial Clinical Dosing of G4544, a New Oral Drug for Bone Diseases
- TransMolecular Reports Positive Phase 2 Data from Study of Iodine Radiolabeled TM-601 in Recurrent Glioma
- Hana Biosciences Initiates Marqibo Phase 2 Clinical Trial in Metastatic Malignant Uveal Melanoma
- Early Results of Phase 2 Trial of Perifosine (KRX-0401) for the Treatment of Recurrent Malignant Gliomas Presented
- Delcath Resumes Enrollment in Phase III and Phase II Trials
- Vertex\'s Collaborator Merck Suspends Patient Enrollment in Clinical Trials of MK-0457 (VX-680) Pending Full Analysis of Clinical Data
- Nexavar First FDA-Approved Drug Therapy for Liver Cancer
- Thallion Announces Positive Safety and Efficacy Data from ECO-4601 Phase I/II Trial
- FDA Clears Advanced Test for Monitoring Metastatic Colorectal Cancer
- Brostallicin Trial Data Demonstrates Encouraging Anti-tumor Activity in Patients With Chemotherapy-Resistant Cancers
- Bristol-Myers Squibb and Pierre Fabre Provide Update On Vinflunine Development Status
- CellSearch Circulating Tumor Cell Kit Receives FDA Clearance for Monitoring Patients with Metastatic Colorectal Cancer
- VioQuest Pharmaceuticals Announces Dosing of First Patient in Phase IIa Solid Tumor Study for Lenocta™, a Novel Protein Tyrosine Phosphatase Inhibitor
- Tasigna® gains European approval for patients with a life-threatening form of leukemia who are resistant or intolerant to existing therapies
- Sativex® Commences US Phase II/III Clinical Trial in Cancer Pain
- GERON INITIATES CLINICAL TRIAL OF TELOMERASE INHIBITOR DRUG IN PATIENTS WITH MULTIPLE MYELOMA
- Lenalidomide (REVLIMID(R)) Receives Orphan Medicinal Product Designation from the European Commission for Chronic Lymphocytic Leukemia
- ArQule Provides Clinical Update on E2F-1 Program
- Announced the Filing for FDA Clearance of the CellSearch™ Circulating Tumor Cell Kit for Monitoring Patients with Metastatic Androgen-Independent Prostate Cancer
- Can-Fite: IND submission for Phase I Clinical Trials with its Drug for Liver Diseases CF102. Can-Fite develops CF102 for the treatment of liver cancer, hepatitis virus infections and other liver conditions that represent a current market of about USD 4 billion. Can-Fite estimates that this Phase I study will be initiated in early 2008, subject to FDA approval
- Amgen Announces Interim Results of Aranesp(R) \'\'PREPARE\'\' Study in Breast Cancer Patients
- TREANDA New Drug Application for the Treatment of Chronic Lymphocytic Leukemia Granted Priority Review Status by FDA
- Vion Pharmaceuticals Announces Initiation of Clinical Trial of Cloretazine♦ (VNP40101M) in Combination with Stem Cell Transplantation
- Serenex Announces Initiation of Second Phase 1
- Metastatix Granted Investigational New Drug (IND) Application for MSX-122
- EntreMed Commences Phase 2 Study with MKC-1 in Pancreatic Cancer
- Celtic Pharma Reports Data Presented at Society for Neuro-Oncology Annual Meeting and Provides Update on XERECEPT Clinical Program
- ADVENTRX Announces Completion of Patient Enrollment in Phase 2 Clinical Trial of CoFactor(R) for the Treatment of Advanced Breast Cancer
- Genzyme Completes Enrollment in Pivotal, Phase 2 Clinical Trial of Clofarabine in Adult AML
- BIOCRYST PROVIDES FORODESINE HCL UPDATE
- Ligand Presents Positive LGD-4665 Phase I Clinical Trial Results at the American Society of Hematology Annual Meeting (ASH)
- Osiris Therapeutics Reports Positive Results for Prochymal(TM) as a Rescue Agent in Pediatric Patients with End-Stage Graft vs. Host Disease
- HEMISPHERX BIOPHARMA RECEIVES NOTICE OF INCOMPLETE NEW DRUG APPLICATION (NDA)
- Pharmion and Methylgene Report Favorable Results for Phase 2 MGCD0103 Single- Agent Studies in Relapsed or Refractory Lymphomas at the 49th American Society of Hematology (ASH) Meeting
- TargeGen Announces Planned Initiation of Clinical Trial of JAK2 Inhibitor TG101348 in Myeloproliferative Disease Patients, and Presentations at ASH
- ASH presentation supports Antisoma\'s AS1411 phase II trial in AML
- Phase III Trial of VELCADE(R) (Bortezomib) for Injection Showed Dramatic Fourfold Increase in Complete Remission Rates When Combined With the Most Commonly Used U.S. Regimen in Front-Line Multiple Myeloma
- Telik Reports Positive Results from Phase 1 Dose-Escalation Study of Telintra Tablets in Myelodysplastic Syndrome
- Phase II Trial of ProMetic’s PBI-1402 Shows Significantly Increased Red Blood Cell Count and Hemoglobin in Chemotherapy-Induced Anemia Patients
- Pharmacyclics Announces Presentation of Results from Phase 1/2 Trial of Xcytrin Plus Zevalin and Preclinical Data with Novel BTK and HDAC Inhibitors
- Keryx Biopharmaceuticals, Inc. Announces Phase 1 and Phase 2 Data on KRX-0401 (Perifosine) in Patients with Relapsed/Refractory Multiple Myeloma at 49th Annual Meeting of American Society of Hematology
- CELSION Re-submits Protocol for Special Protocol Assessment (SPA) for Pivotal Phase III Liver Cancer Trial
- Vion Presents Preliminary Data from its Pivotal Phase II Trial of Cloretazine® (VNP40101M) in Acute Myelogenous Leukemia at ASH Annual Meeting
- TREANDA Significantly Improves Clinical Outcomes in Patients with Chronic Lymphocytic Leukemia Compared to Chlorambucil
- Preliminary Results from VioQuest Pharmaceuticals\' Phase I Trial of Novel Akt Inhibitor VQD-002 in Patients with Advanced Leukemias Demonstrate Promising Clinical Activity
- MDS Patients on Five-Day Vidaza(R) Dosing Schedules Achieve Transfusion Independence Consistent with Seven-day Schedule
- Gloucester Pharmaceuticals Reports Clinically Significant Responses in Pivotal Trial of Romidepsin for Cutaneous T-cell Lymphoma at the 2007 ASH Annual Meeting
- Exelixis Presents Encouraging Phase 1 Data For XL019, A Novel Selective Inhibitor of JAK2
- Chemokine Therapeutics Continues patient Therapy using CTCE-9908 and Extends Closing of its Phase I/II Clinical Trial
- Chroma Announces Positive Phase I Efficacy Data for Novel Cancer Therapy CHR-2797
- Curis, Inc. Reports Decision to Advance a Systemically Administered Hedgehog Antagonist into Phase II Clinical Testing
- Avax Technologies Announces Completion of Melanoma Phase I/II Study
- Idera Pharmaceuticals Initiates Phase 1b Trial of IMO-2055 in Combination with Targeted Agents in Non-Small Cell Lung Cancer
- BIOCRYST ANNOUNCES PRESENTATION OF DATA DETAILING SYNERGISTIC ACTIVITY OF FORODESINE HCL WITH BENDAMUSTINE IN CHRONIC LYMPHOCYTIC LEUKEMIA (CLL)
- Taxotere®-Based Chemotherapy Significantly Improved Overall Survival Compared With Standard Anthracycline-Based Chemotherapy In Early Stage Breast Cancer
- SuperGen Reports Initiation of Multi-arm Phase 1b Trial of Novel Tyrosine Kinase Inhibitor
- Pivotal Phase 3 Data Show Denosumab Increased Bone Density Throughout Skeleton in Non-Metastatic Breast Cancer Patients on Adjuvant Aromatase Inhibitor Therapy
- Kosan\'s Hsp90 Inhibitor, Tanespimycin, Shows 55% Clinical Benefit in Patients With Trastuzumab-Refractory Metastatic Breast Cancer
- GlaxoSmithKline announces data on Tykerb ® (lapatinib) plus capecitabine for the treatment of HER2-positive breast cancer brain metastases
- Genzyme Announces FDA Approval of Thyrogen For Use In Thyroid Cancer Ablation
- Endo Announces Positive Results From Interim Analysis of RAPINYL(TM) Phase III Clinical Trial
- Data Show ARIMIDEX® (anastrozole) Continues To Be Superior To Tamoxifen In Helping Reduce The Risk Of Recurrence In Patients With Early Breast Cancer
- PTC Therapeutics Presents Encouraging Phase 1 Results of its Novel VEGF Inhibitor, PTC299, at 30th Annual San Antonio Breast Cancer Symposium
- Cell Therapeutics, Inc. (CTI) to Submit Marketing Authorization Application for XYOTAX(TM) for First-line Non-small Cell Lung Cancer Ahead of Schedule
- Angiotech Submits 510(K) to FDA for its Innovative 5-FU CVC
- Avastin approved in Europe for first-line treatment of patients with advanced kidney cancer
- Critical Outcome Technologies Inc. Announces Intentions to Prepare a Phase 1B Health Canada Clinicial Trial Submission
- BioSphere Medical Receives CE Mark Approval for Transarterial Chemoembolization Using HepaSphere(TM) Microspheres
- Indevus Receives Non-Approvable Letter From FDA for VALSTAR
- Peregrine Pharmaceuticals Remains on Track to Advance its Three Lead Clinical Programs in 2008
- Introgen Plans to Expand Biomarker Database in Phase 3 Trials and File BLA and MAA for ADVEXIN in Advanced Head and Neck Cancer in First Half of 2008
- Infinity and MedImmune Initiate Phase 2 Trial of IPI-504 to Assess the Hsp90 Inhibitor\'s Potential Anti-Tumor Activity in Patients with Advanced Non-Small Cell Lung Cancer
- Human Genome Sciences Initiates Second Randomized Phase 2 Trial of HGS-ETR1 in Combination with Chemotherapy
- CuraGen and TopoTarget Announce Initiation of an NCI-sponsored Phase II Clinical Trial of Belinostat for Thymoma and Thymic Carcinoma
- Update on Phase 3 Clinical Program for PI-88 in Liver Cancer
- Cougar Biotechnology Initiates Phase I Trial for CB3304 (Noscapine)
- Pharmacyclics Receives Non-Approvable Letter from the FDA for Xcytrin for the Treatment of Lung Cancer Brain Metastases
- Altor BioScience Advances Clinical Trial for Targeted Cancer Therapeutic, ALT-801
- Allos Therapeutics Initiates Phase 2b Study of PDX in Patients With Non-small Cell Lung Cancer
- OXiGENE Reports Positive Results in Phase 2 Study of ZYBRESTAT(TM) in Platinum-Resistant Ovarian Cancer
- Cephalon Submits New Drug Application for TREANDA for the Treatment of Patients with Relapsed Indolent Non-Hodgkin\'s Lymphoma
- Cyclacel initates phase 2 sapacitabine trial in elderly AML patients
- NEOPHARM Announces IND Filing for Novel Liposomal Delivery System of Docetaxel
- EntreMed Announces FDA Acceptance of IND Application for Aurora Kinase/Angiogenesis Inhibitor, ENMD-2076
- Kosan Opens TIME-1 Pivotal Phase 3 Trial in Multiple Myeloma
- HELSINN AND MGI PHARMA ANNOUNCE sNDA FOR ALOXI CAPSULES ACCEPTED FOR REVIEW BY U.S. FDA
- ZymoGenetics Begins Phase 2 Trial in Renal Cell Cancer Evaluating IL-21 Combined with Nexavar(R)
- TransMolecular Receives Orphan Drug Designation for Non-radiolabeled TM601 for the Treatment of Malignant Glioma
- Seattle Genetics Earns Milestone Payment from Initiation of SGN-40 Phase Ib Clinical Trial in Combination with Rituxan for Non-Hodgkin Lymphoma
- Maxygen Announces Positive Progress in Phase IIa Clinical Trial of Novel PEG-GCSF
- Can-Fite Receives FDA Approval to Conduct Phase I Study with CF102
- Exelixis Initiates Phase 1/2 Trial of XL184 in Patients With Non-Small Cell Lung Cancer
- BSD Medical Receives Letter from FDA on BSD-2000
- Nektar Commences Phase 2 Clinical Development Program for NKTR-102 (PEG-Irinotecan) in Colorectal Cancer
- Can-Fite Receives FDA Approval to Conduct Phase I Study with CF102
- Chemokine Therapeutics Receives Approval From FDA to Commence Phase II Study
- Vion Announces FDA Lift of Clinical Hold on Phase III Study of Cloretazine® (VNP40101M) and Cytarabine in Relapsed AML
- MethylGene and Pharmion Start Phase II Combination Clinical Trial with MGCD0103 and Vidaza(R) in Patients with Relapsed or Refractory Hodgkin Lymphoma or Non-Hodgkin Lymphoma
- BioCancell gets FDA approval for Phase IIb Bladder Cancer clinical trial
- ADVENTRX Announces ANX-530 Safety Data and Provides NDA Submission Guidance
- FDA Extends Review Of GENASENSE® NDA Appeal in Chronic Lymphocytic Leukemia
- Kosan Initiates Phase 2 Trial of Alvespimycin, Second-Generation Hsp90 Inhibitor, in HER2-Positive Metastatic Breast Cancer
- Dako receives FDA approval of TOP2A FISH pharmDx
- Protox Initiates Phase 2 Prostate Cancer Study
- SGX Initiates Phase I Trials for SGX523
- Celsion To Proceed With Phase II Pivotal Breast Cancer Trial After Receiving Supportive FDA Response
- Fermiscan begins clinical trial in Singapore for breast cancer detection
- Adherex Announces Phase IIb Expansion of ADH-1 Combination Study In Melanoma
- Synta Pharmaceuticals Initiates Second Phase 1 Clinical Trial of STA-9090, A Novel Hsp90 Inhibitor
- MGI PHARMA Announces Results from Study Involving the Dual Implantation of Gliadel(R) Wafer and Radioactive Seeds for Treatment of Recurrent Glioblastoma Multiforme
- Phase II Study of Zevalin(R) Consolidation Following Fludarabine and Mitoxantrone Chemotherapy Results in 100 Percent Complete Remission Rate and 89 Percent Three-Year Progression Free Survival in Patients with Previously Untreated Non-Follicular Indolent
- Xanthus Announces Oral Fludarabine NDA Accepted for Review by U.S. FDA
- EntreMed Commences Phase 2 Study With MKC-1 in Ovarian/Endometrial Cancers
- Celprogen Launches Caner Stem Cells
- Thalidomide Pharmion(R) Receives Positive Opinion for Treatment of First-line Multiple Myeloma from European Medicines Agency
- Takeda Doses First Patient in A U.S. Phase 1 Study of Hematide to Treat Chemotherapy Induced Anemia
- Cephalon\'s EFFENTORA Receives Positive Opinion from European Regulatory Authorities for the Management of Breakthrough Cancer Pain
- GlaxoSmithKline and Synta announce elesclomol granted US orphan drug designation by the FDA
- Start of OncoGel Phase 2b Study in Oesophageal Cancer
- Poniard Pharmaceuticals Announces Picoplatin Safety Data in Colorectal Cancer
- EntreMed Presents Interim Results for Phase 2 Carcinoid Tumor Study
- Interim Safety Data Presented on Vectibix(TM) (Panitumumab) in Combination with Standard Chemotherapy
- WILEX receives US FDA approval (IND) for clinical Phase II trial with its uPA inhibitor WX-671 in metastatic breast cancer
- Peregrine Pharmaceuticals Opens Enrollment in Phase II Clinical Trial of Bavituximab in Patients with Advanced Breast Cancer
- Pro-Pharmaceuticals Phase ll Trial Shows DAVANAT® Improves Median Progression Free Survival with Fewer Side Effects as Compared to Recent Similar Studies.
- Alfacell Updates Status of ONCONASE Phase III Clinical Program
- AVEO Initiates Phase 1b Combination Clinical Trial of Novel Triple VEGF Receptor Inhibitor AV-951 in Metastatic Renal Cell Carcinoma
- TargeGen Announces Initiation of Clinical Trial of JAK2 Inhibitor TG101348 in Myeloproliferative Disease Patients
- Eisai Announces Change in U.S. Submission Schedule for E7389 New Drug Application
- Alchemia announces successful Pre-IND meeting with the US FDA
- FDA Grants Orphan Drug Designation for Novel Akt Inhibitor VQD-002 in Multiple Myeloma
- View Summary ZIOPHARM Commences Treatment of First Patients in Two Separate Phase I/II Combination Studies of Both Indibulin and Palifosfamide
- SciClone Initiates Phase 2 Trial of RP101 in Late-Stage Pancreatic Cancer Patients
- GlaxoSmithKline receives EMEA positive opinion for the approval of Hycamtin® (topotecan) hard capsules for the treatment of relapsed small cell lung cancer
- Thallion Completes Patient Enrollment in Phase II Trial for CAP-232
- EMEA Accepts for Review Vidaza(R) Marketing Authorization Application for Higher-Risk Myelodysplastic Syndromes
- Spectrum Pharmaceuticals Initiates Phase 1 Study of SPI-1620, a Novel Adjunct to Cancer Chemotherapy
- VGX Pharmaceuticals announces the IND filing of VGX-3200, a novel DNA therapy that utilizes GHRH for the treatment of cancer cachexia and anemia
- deCODE launches a DNA-based test for assessing risk of prostate cancer on the back of the discovery of new prostate cancer genes
- Sosei Announces Start of AD 923 Phase III Studies in Europe
- METHYLGENE AND PHARMION ANNOUNCE ORPHAN DRUG DESIGNATION GRANTED BY THE EUROPEAN MEDICINES AGENCY (EMEA) FOR MGCD0103 FOR THE TREATMENT OF ACUTE MYELOGENOUS
- Hana Biosciences Announces Top-Line Phase 1 Clinical Trial Data Demonstrating Alocrest to be Well-Tolerated With Promising Anti-Tumor Activity
- Clinical Update – Decapeptyl®/Trelstar® 6-Month Formulation in Advanced Prostate Cancer
- Æterna Zentaris Reports First Patients Treated with Anti-Cancer Compound AEZS-108 in Phase 2 Trial in Ovarian and Endometrial Cancers
- Hana Biosciences Announces Top-Line Phase 1 Clinical Trial Data Demonstrating Alocrest to be Well-Tolerated With Promising Anti-Tumor Activity
- Clinical Update – Decapeptyl®/Trelstar® 6-Month Formulation in Advanced Prostate Cancer
- Cougar Biotechnology Presents Positive CB7630 Phase I and Phase II Data at ASCO 2008 Genitourinary Cancers Symposium
- OncoGenex Reports Lead Drug Candidate OGX-011 Achieved Primary Endpoint in Phase 2 Trail With Second-Line Chemotherapy for Prostate Cancer
- Bayer and Onyx Provide Update on Phase 3 Trial of Nexavar in Patients With Non-Small Cell Lung Cancer
- Can-Fite Initiated Phase I Clinical Trial with CF102
- Spectrum Pharmaceuticals Receives Approval from Canadian Authorities to Expand EOquin(R) Registrational, Phase 3 Clinical Trials into Canada
- Poniard Pharmaceuticals Announces Positive First-line Phase 1 Safety and Efficacy Data With Picoplatin in Metastatic Prostate Cancer Patients
- Hollis-Eden Pharmaceuticals Announces Filing of IND with APOPTONE(TM) in Hormone Sensitive Cancers to Commence Phase I/II Clinical Trial in Late-Stage Prostate Cancer
- Lenalidomide (REVLIMID(R)) Receives Orphan Drug Status in Japan for Multiple Indications
- FDA Accepts TREANDA(R) New Drug Application for the Treatment of Relapsed Indolent Non-Hodgkin\'s Lymphoma
- Bionovo Announces Positive Developments in On-going Phase 1/2 Cancer Drug Trial
- Algeta receives IND approval for Alpharadin(TM) to commence clinical development in the USA
- Millennium Expands VELCADE(R) (Bortezomib) For Injection Program In Non-Hodgkin\'s Lymphoma
- Kiadis Pharma obtains FDA approval to start a phase III clinical trial for Reviroc™ in the United States. FDA approves IND application for Reviroc
- GTx\'s Toremifene Citrate 80 mg Meets Primary and Key Endpoints in Phase III Trial in Advanced Prostate Cancer Patients on Androgen Deprivation Therapy
- FDA Grants Accelerated Approval of Avastin in Combination With Paclitaxel Chemotherapy for First-Line Treatment of Advanced HER2-Negative Breast Cancer
- VioQuest Pharmaceuticals Enters Into Clinical Trial Agreement for Novel Akt Inhibitor VQD-002 with the National Cancer Institute
- TREATMENT OF FIRST PATIENT IN PHASE I CLINICAL TRIAL OF BIONOMICS’ ANTI-CANCER DRUG BNC105
- AstraZeneca Provides Update On RECENTIN Clinical Development Programme
- CellSearch™ Now Indicated For Metastatic Prostate Cancer
- EpiCept Announces Non-Binding Opinion by European Regulatory Authority on Ceplene Marketing Application
- Everolimus (RAD001) significantly extends progression-free survival in advanced kidney cancer patients after failure of other targeted therapy
- GTx\'s Announces Additional Top Line Phase III Data Demonstrating Toremifene Citrate 80 mg Reduced Hot Flashes in Men with Prostate Cancer on Androgen Deprivation Therapy
- Sequenom Releases Cancer EpiPanel for High-Throughput Methylation Profiling of Cancer-Associated Genes
- CTI Submits European Marketing Authorization Application for XYOTAX(TM)
- ProMetic reports continued positive data in PBI-1402 Phase II trial in chemotherapy-induced anemia
- ActivBiotics Receives FDA Orphan Drug Designation for Superoxide Dismutase Mimetic, M40403, in Oral Mucositis of Cancer
- FDA Approval of Drug-Eluting Bead Clinical Trial
- Progen Announces Commencement of Global Phase 3 Trial
- Sunesis Pharmaceuticals Reports Positive Interim Data for SNS-595 Single-Agent Activity in Platinum-Resistant Ovarian Cancer
- Peregrine Pharmaceuticals Announces Positive Data From Cotara Brain Cancer Trials
- ChemGenex Launches Multi-Site Omacetaxine Clinical Trial in AML Patients
- FDA Approves New Drug Application (NDA) for LEVOleucovorin, Spectrum\'s First Proprietary Oncology Drug
- FDA Agrees to Amend Dendreon\'s Special Protocol Assessment for Phase 3 IMPACT Study of PROVENGE
- Celsion Commences Global Phase III Study for Primary Liver Cancer
- NOVELOS THERAPEUTICS REACHES TARGET ENROLLMENT IN PIVOTAL PHASE 3 LUNG CANCER TRIAL
- Anti-cancer drug CYT997 update
- ArQule Enrolls First Patient in Phase 1/2 Clinical Trial Program of ARQ 197 in Non-Small Cell Lung Cancer
- Amgen Statement on Successful Outcome of Romiplostim Panel Meeting
- AstraZeneca Completes Enrollment In Two Pivotal Phase III Studies Of The Investigational Drug Vandetanib (ZACTIMA®) In Non-Small Cell Lung Cancer (NSCLC)
- Printer Friendly Version Fludarabine, Mitoxantrone and Zevalin(R) Produces 96% Complete Remission Rate in First-Line Treatment of Patients with Follicular Non-Hodgkin\'s Lymphoma
- Abraxis Bioscience Announces Filing of Marketing Application in Japan for ABRAXANE in the Treatment of Breast Cancer
- Tyverb (lapatinib) European regulatory update
- Seattle Genetics Initiates SGN-33 Clinical Trial in Combination with Revlimid(R) for Myelodysplastic Syndromes (MDS)
- Supplemental Application for GARDASIL®, Merck\'s Cervical Cancer Vaccine, Designated Priority Review by the U.S. FDA for Use in Women 27 through 45
- Vermillion Announces Positive Results From Clinical Trial of Ovarian Tumor Triage Test; Study Meets Primary Endpoints
- ProNAi Therapeutics, Inc. Cleared to Begin Phase I Clinical Trials for the First DNA Interference (DNAi) Therapeutic
- Cephalon Receives FDA Approval for TREANDA, a Novel Chemotherapy for Chronic Lymphocytic Leukemia
- CTI Announces Enrollment Complete in Phase III EXTEND (PIX301) Clinical Trial of Pixantrone in Patients With Second or Greater Relapse of Diffuse Large B Cell NHL
- Array BioPharma Advances p38 / Tie2 Inhibitor, ARRY-614, into Phase 1 Clinical Trial
- Amrubicin(R) Receives FDA Orphan Drug Designation for the Treatment of Small Cell Lung Cancer
- OXiGENE Begins Phase II NSCLC Trial of ZYBRESTAT(TM) in Combination with Bevacizumab and Chemotherapy
- Adherex Announces Phase III Trial With STS in Collaboration With the Children\'s Oncology Group
- SGX Pharmaceuticals Provides Update on SGX523 Clinical Trials
- Trubion Initiates Phase 1/2 Study of TRU-016 in CLL, Announces Next-Generation Product Candidate for RA and Provides Product Pipeline Update
- Phase II results for CDP791 in non-small cell lung cancer support further clinical development
- FAST Clinical Trial FDA Approved
- Gen-Probe Begins U.S. Clinical Study of Molecular Test for Human Papillomavirus, Which Causes Cervical Cancer
- Cougar Biotechnology Announces Agreement with FDA on Special Protocol Assessment for Phase III trial of CB7630 (Abiraterone Acetate)
- Alfacell Updates Status of ONCONASE(R) Phase III Clinical Program
- NOVELOS THERAPEUTICS ANNOUNCES CONTINUED ENCOURAGING RESULTS IN ONGOING PHASE 2 OVARIAN CANCER TRIAL AT DANA-FARBER/HARVARD CANCER CENTER
- EntreMed Commences Continuous Dosing Clinical Trial For MKC-1
- Hana Biosciences Commences Phase 1 Clinical Trial of Topical Menadione for Treatment and/or Prevention of EGFR Inhibitor-Associated Skin Rash
- EpiCept Announces Positive Clinical Data from EPC2407 Phase I Cancer Trial
- Oncophage® Approved in Russia for the Treatment of Intermediate-Risk Kidney Cancer
- Seattle Genetics Announces Initiation of Phase Ib Clinical Trial of SGN-40 in Combination with Rituxan and Gemzar for Non-Hodgkin Lymphoma
- Abraxis BioScience Announces Approval to Market ABRAXANE for Metastatic Breast Cancer in Korea
- EntreMed Achieves a Key Milestone Through Initiation of ENMD-2076 Clinical Program
- ArQule Provides Clinical Update on E2F-1 Program
- ASA404, a novel cancer agent, begins pivotal trial to explore new approach in treating lung cancer, the leading cause of cancer death
- Poniard Pharmaceuticals\' Oral Picoplatin Demonstrates Positive Bioavailability in Ongoing Phase 1 Trial
- Cephalon Announces European Commission Approval of EFFENTORA for the Treatment of Breakthrough Cancer Pain
- Kosan Initiates Phase 2 Trial of Epothilone KOS-1584 in Non-Small Cell Lung Cancer
- New Data Continues To Support The Safety And Clinical Activity For Celsion’s Thermodox In Recurrent Breast Cancer
- New Phase III Data Confirm Phase II Findings of ADVEXIN(R) Efficacy
- Medivation Announces Presentation of Positive MDV3100 Clinical Data in Castration-Resistant Prostate Cancer Patients
- Curis Announces GDC-0449 Phase I Clinical Data
- AVEO Pharmaceuticals’ Novel Triple VEGF Receptor Inhibitor Shows Tumor Regression in Patients with Advanced Renal Cancer; Clinical Activity and Tolerability in other Solid Tumors including Colon and Lung Cancers
- ANX-530 Demonstrates Equivalent Pharmacokinetics to Navelbine(R) in a Registrational Bioequivalence Clinical Study
- Celator Pharmaceuticals Successfully Uses Nanoparticles to Administer Hydrophobic Drug Combinations
- ZIOPHARM Presents Positive Data from Phase II Study of Darinaparsin in Advanced Hematological Malignancies at AACR 2008 Annual Meeting
- Repligen Receives FDA Fast Track Designation for RG1068 for Pancreatic Imaging
- MethylGene initiates MGCD265 Phase I clinical trial
- Angiotech\'s Novel 5-FU Central Venous Catheter Receives FDA 510(k) Clearance
- Abraxis BioScience Reports Promising Clinical Data in Advanced Pancreatic Cancer Using a Combination of nab-Paclitaxel (ABRAXANE(R)) and Gemcitabine (Gemzar(R))
- Allos Therapeutics Completes Patient Enrollment in Pivotal Phase 2 PROPEL Trial of PDX in Patients with Peripheral T-cell Lymphoma
- Poniard Pharmaceuticals Announces Final Picoplatin Data from Phase 2 Small Cell Lung Cancer Trial Demonstrating Survival Benefit
- ORAL PBI-1402 DEMONSTRATES SIGNIFICANT ACTIVITY IN CHEMOTHERAPY-INDUCED ANEMIA PHASE II CLINICAL TRIAL
- Cougar Biotechnology Announces Initiation of Phase III Trial of CB7630 (Abiraterone Acetate)
- PRO-PHARMACEUTICALS UPDATES NDA FILING FOR DAVANAT
- Oncothyreon files investigational new drug application for PX-866 oncology compound
- HER1 and HER3 VeraTag Assays are Now Available for Use in Development and Clinical Evaluation of Cancer Therapeutics
- Curis Announces Genentech\'s Initiation of Hedgehog Antagonist Phase II Clinical Trial In Metastatic Colorectal Cancer
- Molecular Insight Pharmaceuticals, Inc. Initiates Phase 2a Azedra Clinical Trial in Neuroblastoma Patients
- Poniard Pharmaceuticals Completes Enrollment of Phase 2 Picoplatin Trial in Colorectal Cancer
- OncoVista Innovative Therapies, Inc. Announces Submission of Request for pre-IDE Meeting
- BiPar Sciences Expands Phase 2 Clinical Trials of BSI-201, a Novel DNA Repair Inhibitor, in Ovarian Cancer
- Novel Anti-Cancer Drug Development Collaboration
- Dana-Farber Cancer Institute Commences Phase 1 Trial With EntreMed’s Selective Kinase Inhibitor
- Vion Announces Initiation of Clinical Trial of Cloretazine® (VNP40101M) in Combination with Cytarabine
- ZIOPHARM Receives FDA Orphan Drug Designation for Palifosfamide (ZIO-201) in the Treatment of Soft Tissue Sarcoma
- Thallion Receives Health Canada Approval to Initiate Phase II for TLN-4601 in Brain Cancer
- Active Biotech advances ANYARA into Phase III clinical trial
- Oncolytics Biotech Inc. Announces U.K. Phase II Clinical Trial Investigating REOLYSIN® in Combination with Paclitaxel and Carboplatin
- Progen Resumes Phase 1 Development of Anti-Cancer Agent PG11047
- Allos Therapeutics Reports Interim Response and Safety Data from Pivotal Phase 2 PROPEL Trial
- Nexavar Significantly Extends Overall Survival in Liver Cancer by 47 percent
- GSK announces results of first Phase III trial evaluating Tykerb®/Tyverb (lapatinib) plus Herceptin (trastuzumab)
- Array BioPharma and AstraZeneca Announce New Phase 2 Development Plans for the Investigational Anti-Cancer Drug AZD6244 (ARRY-886)
- ADVENTRX Announces ANX-530 Safety Data from Registrational Bioequivalence Clinical Study
